<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02135952</url>
  </required_header>
  <id_info>
    <org_study_id>SISNEP/697</org_study_id>
    <secondary_id>2013/01072-5</secondary_id>
    <nct_id>NCT02135952</nct_id>
  </id_info>
  <brief_title>Metronidazole and Amoxicillin for the Treatment of Type 2 Diabetic Subjects With Periodontitis</brief_title>
  <official_title>Metronidazole and Amoxicillin as Adjuncts to Scaling and Root Planing for the Treatment of Type 2 Diabetic Subjects With Periodontitis: a Randomized Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guarulhos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guarulhos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes mellitus (DM) is a widely prevalent disease associated with several major systemic
      and oral complications, such as periodontitis. The use of adjunctive local and/or systemic
      antimicrobials has been proposed to improve the clinical and glycemic outcomes of the scaling
      and root planing (SRP) in diabetic subjects. The combination of metronidazole (MTZ) and
      amoxicillin (AMX) has been largely recognized as an effective therapy for improving the
      clinical and microbiological outcomes of SRP in the treatment of with chronic periodontitis
      (ChP). However, no previous clinical trials to date have evaluated the effects of this
      antibiotic combination in the treatment of diabetic subjects with periodontitis. Therefore,
      the aim of this randomized clinical trial (RCT) will be to evaluate the clinical and
      microbiological effects of the use of MTZ+AMX as adjuncts to SRP for the treatment of type 2
      diabetic subjects with generalized ChP.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in number of sites with probing depth (PD) ≥5 mm post-treatment</measure>
    <time_frame>From baseline to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD and clinical attachment level (CAL) changes at initially moderate sites</measure>
    <time_frame>From baseline to 12 months and from baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD and CAL changes at initially deep sites</measure>
    <time_frame>From baseline to 12 months and from baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in number of sites with PD ≥5mm</measure>
    <time_frame>From baseline to 12 months and from baseline to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-mouth PD and CAL</measure>
    <time_frame>Baseline, 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-mouth percentages of sites with plaque</measure>
    <time_frame>Baseline, 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-mouth percentages of sites with marginal bleeding</measure>
    <time_frame>Baseline, 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-mouth percentages of sites with bleeding on probing</measure>
    <time_frame>Baseline, 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-mouth percentages of sites with suppuration</measure>
    <time_frame>Baseline, 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-mouth percentages of sites with PD ≥5mm</measure>
    <time_frame>Baseline, 3, 6,12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of glycated hemoglobin (HbA1c)</measure>
    <time_frame>Baseline, 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of fasting plasma glucose FPG</measure>
    <time_frame>Baseline, 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of periodontal pathogenic bacterial species</measure>
    <time_frame>Baseline, 3, 6, 12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>SRP+MTZ+AMX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Scaling and root planing (SRP) + metronidazole (MTZ; 400 mg thrice a day [TID] for 14 days) + amoxicillin (AMX; 500 mg TID for 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRP+placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Scaling and root planing + placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SRP</intervention_name>
    <description>SRP in four to six appointments lasting approximately 1 h each, using manual curettes and ultrasonic device under local anesthesia.</description>
    <arm_group_label>SRP+MTZ+AMX</arm_group_label>
    <arm_group_label>SRP+placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo for 14 days started immediately after the first session of SRP.</description>
    <arm_group_label>SRP+placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTZ+AMX</intervention_name>
    <description>Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.</description>
    <arm_group_label>SRP+MTZ+AMX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 35 years of age

          -  Diagnosis of type 2 DM for ≥ 5 years

          -  DM treatment with diet and insulin supplementation or oral hypoglycemic agents

          -  Glycated hemoglobin (HbA1c) levels ≥ 6.5% ≤ 11%

          -  At least 15 teeth

          -  More than 30% of the sites with probing depth (PD) and clinical attachment level (CAL)
             ≥ 4 mm

          -  Minimum of six teeth with at least one site with PD and CAL ≥ 5 mm and bleeding on
             probing (BoP) at baseline.

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  Current smoking

          -  Smoking within the past 5 years

          -  Scaling and root planing (SRP) in the previous 12 months

          -  Antimicrobial therapies during the previous 6 months

          -  Medical conditions requiring prophylactic antibiotic coverage

          -  Continuous use of mouthrinses containing antimicrobials in the preceding 3 months

          -  Systemic conditions (except DM) that could affect the progression of periodontitis
             (e.g. immunological disorders, osteoporosis)

          -  Long-term administration of anti-inflammatory

          -  Long-term administration of immunosuppressive medications

          -  Allergy to metronidazole and/or amoxicillin

          -  Presence of periapical pathology

          -  Use of orthodontic appliances

          -  Presence of extensive prosthetic rehabilitation

          -  Major complications of DM (i.e. cardiovascular and peripheral vascular diseases
             [ulcers, gangrene and amputation], neuropathy and nephropathy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poliana M Duarte, PhG</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guarulhos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Guarulhos</name>
      <address>
        <city>Guarulhos</city>
        <state>São Paulo</state>
        <zip>07023-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Amid R, Tabeie MB, Kadkhodazadeh M, Mehdizadeh AR, Youssefi N. Local concentration of systemic amoxicillin and metronidazole in healthy and inflamed gingiva: a comparative in vivo study. Drug Metabol Drug Interact. 2012 May 10;27(2):113-8. doi: 10.1515/dmdi-2012-0003.</citation>
    <PMID>22706234</PMID>
  </reference>
  <reference>
    <citation>Borgnakke WS, Ylöstalo PV, Taylor GW, Genco RJ. Effect of periodontal disease on diabetes: systematic review of epidemiologic observational evidence. J Clin Periodontol. 2013 Apr;40 Suppl 14:S135-52. doi: 10.1111/jcpe.12080. Review.</citation>
    <PMID>23627324</PMID>
  </reference>
  <reference>
    <citation>Cionca N, Giannopoulou C, Ugolotti G, Mombelli A. Amoxicillin and metronidazole as an adjunct to full-mouth scaling and root planing of chronic periodontitis. J Periodontol. 2009 Mar;80(3):364-71. doi: 10.1902/jop.2009.080540 .</citation>
    <PMID>19254119</PMID>
  </reference>
  <reference>
    <citation>Cionca N, Giannopoulou C, Ugolotti G, Mombelli A. Microbiologic testing and outcomes of full-mouth scaling and root planing with or without amoxicillin/metronidazole in chronic periodontitis. J Periodontol. 2010 Jan;81(1):15-23. doi: 10.1902/jop.2009.090390.</citation>
    <PMID>20059413</PMID>
  </reference>
  <reference>
    <citation>Feres M. Antibiotics in the treatment of periodontal diseases: microbiological basis and clinical applications. Ann R Australas Coll Dent Surg. 2008 Jun;19:37-44. Review.</citation>
    <PMID>19728628</PMID>
  </reference>
  <reference>
    <citation>Feres M, Soares GM, Mendes JA, Silva MP, Faveri M, Teles R, Socransky SS, Figueiredo LC. Metronidazole alone or with amoxicillin as adjuncts to non-surgical treatment of chronic periodontitis: a 1-year double-blinded, placebo-controlled, randomized clinical trial. J Clin Periodontol. 2012 Dec;39(12):1149-58. doi: 10.1111/jcpe.12004. Epub 2012 Sep 27.</citation>
    <PMID>23016867</PMID>
  </reference>
  <reference>
    <citation>Grossi SG, Skrepcinski FB, DeCaro T, Robertson DC, Ho AW, Dunford RG, Genco RJ. Treatment of periodontal disease in diabetics reduces glycated hemoglobin. J Periodontol. 1997 Aug;68(8):713-9.</citation>
    <PMID>9287060</PMID>
  </reference>
  <reference>
    <citation>Jimenez M, Hu FB, Marino M, Li Y, Joshipura KJ. Type 2 diabetes mellitus and 20 year incidence of periodontitis and tooth loss. Diabetes Res Clin Pract. 2012 Dec;98(3):494-500. doi: 10.1016/j.diabres.2012.09.039. Epub 2012 Oct 3.</citation>
    <PMID>23040240</PMID>
  </reference>
  <reference>
    <citation>Lang NP, Tonetti MS. Periodontal risk assessment (PRA) for patients in supportive periodontal therapy (SPT). Oral Health Prev Dent. 2003;1(1):7-16.</citation>
    <PMID>15643744</PMID>
  </reference>
  <reference>
    <citation>Silva MP, Feres M, Sirotto TA, Soares GM, Mendes JA, Faveri M, Figueiredo LC. Clinical and microbiological benefits of metronidazole alone or with amoxicillin as adjuncts in the treatment of chronic periodontitis: a randomized placebo-controlled clinical trial. J Clin Periodontol. 2011 Sep;38(9):828-37. doi: 10.1111/j.1600-051X.2011.01763.x. Epub 2011 Jul 15.</citation>
    <PMID>21762197</PMID>
  </reference>
  <reference>
    <citation>Zandbergen D, Slot DE, Cobb CM, Van der Weijden FA. The clinical effect of scaling and root planing and the concomitant administration of systemic amoxicillin and metronidazole: a systematic review. J Periodontol. 2013 Mar;84(3):332-51. doi: 10.1902/jop.2012.120040. Epub 2012 May 21. Review.</citation>
    <PMID>22612369</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2014</study_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guarulhos</investigator_affiliation>
    <investigator_full_name>Poliana Mendes Duarte</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Periodontitis</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

